Investigation Into MacroGenics (MGNX) Announced by Hagens Berman
One MacroGenics Insider Raised Stake By 83% In Previous Year
Insiders were net buyers of MacroGenics, Inc.'s (NASDAQ:MGNX ) stock during the past year. That is, insiders bought more stock than they sold. Although we don't think shareholders should simply
MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman
MacroGenics (NASDAQ:MGNX Shareholders Incur Further Losses as Stock Declines 16% This Week, Taking Three-year Losses to 82%
Every investor on earth makes bad calls sometimes. But you have a problem if you face massive losses more than once in a while. So take a moment to sympathize with the long term shareholders of Macr
MacroGenics to Participate in Upcoming Investor Conference
MacroGenics to Participate in Upcoming Investor Conference ROCKVILLE, MD, June 11, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing,
Shareholders in MacroGenics (NASDAQ:MGNX) Are in the Red If They Invested Three Years Ago
Express News | Millennium Management LLC Reports 5.1% Passive Stake in MacroGenics Inc as of June 3 - SEC Filing
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results.SAIC reported a 9% revenue decline year over year in the fiscal first qua
Demystifying Macrogenics: Insights From 14 Analyst Reviews
Analysts' ratings for Macrogenics (NASDAQ:MGNX) over the last quarter vary from bullish to bearish, as provided by 14 analysts.In the table below, you'll find a summary of their recent ratings, reveal
Macrogenics Is Maintained at Buy by BTIG
Macrogenics Is Maintained at Buy by BTIG
Macrogenics Price Target Cut to $9.00/Share From $24.00 by BTIG
Macrogenics Price Target Cut to $9.00/Share From $24.00 by BTIG
Express News | BTIG Maintains Buy on Macrogenics, Lowers Price Target to $9
B.Riley Financial Maintains Macrogenics(MGNX.US) With Buy Rating, Cuts Target Price to $18
B.Riley Financial analyst Mayank Mamtani maintains $Macrogenics(MGNX.US)$ with a buy rating, and adjusts the target price from $25 to $18.According to TipRanks data, the analyst has a success rate of
Analysts Are Bullish on These Healthcare Stocks: MacroGenics (MGNX), Iovance Biotherapeutics (IOVA)
Express News | MacroGenics Inc : Btig Cuts Target Price to $9 From $24
BTIG Maintains Macrogenics(MGNX.US) With Buy Rating, Cuts Target Price to $9
BTIG analyst Kaveri Pohlman maintains $Macrogenics(MGNX.US)$ with a buy rating, and adjusts the target price from $24 to $9.According to TipRanks data, the analyst has a success rate of 32.9% and a to
Express News | MacroGenics Inc : Citigroup Cuts Target Price to $16 From $25
Analysts Offer Insights on Healthcare Companies: MacroGenics (MGNX) and Bruker (BRKR)
Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment
USA News Group – A new study is bringing hope in the fight against one of the deadliest cancers, revealing a blood test that can detect early-stage...
FFIE, OGEN and CCLD Among Mid-day Movers